KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Cash from Financing Activities (2016 - 2023)

TherapeuticsMD's Cash from Financing Activities history spans 13 years, with the latest figure at $2.0 million for Q4 2023.

  • For Q4 2023, Cash from Financing Activities rose 101.79% year-over-year to $2.0 million; the TTM value through Dec 2023 reached -$108.2 million, up 54.0%, while the annual FY2023 figure was $3.2 million, 101.34% up from the prior year.
  • Cash from Financing Activities reached $2.0 million in Q4 2023 per TXMD's latest filing, up from -$1000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $111.7 million in Q2 2019 to a low of -$120.0 million in Q2 2022.
  • Average Cash from Financing Activities over 5 years is $9.2 million, with a median of $890500.0 recorded in 2021.
  • Peak YoY movement for Cash from Financing Activities: surged 48669.82% in 2020, then crashed 28137.38% in 2022.
  • A 5-year view of Cash from Financing Activities shows it stood at $77.0 million in 2019, then tumbled by 58.84% to $31.7 million in 2020, then plummeted by 95.73% to $1.4 million in 2021, then crashed by 8373.84% to -$111.9 million in 2022, then surged by 101.79% to $2.0 million in 2023.
  • Per Business Quant, the three most recent readings for TXMD's Cash from Financing Activities are $2.0 million (Q4 2023), -$1000.0 (Q3 2023), and -$111.9 million (Q4 2022).